Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)

Clinical trial NCT04510818 · UNKNOWN

Trial details

NCT number: NCT04510818
Sponsor: Ruijin Hospital
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Head and Neck Cancer Esophageal Squamous Cancer

Start date: 2020-08-01
Primary completion: 2022-08-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.